Medtronic, Qualcomm Join Forces to Develop CGMs
Device giant Medtronic has reached an agreement with Qualcomm’s San Diego, Calif.-based subsidiary — Qualcomm Life — to develop Type 2 diabetes glucose monitoring systems.
Under the multi-year agreement, both companies will focus on developing a single-use, low-cost CGM, which will include a new sensor and smaller design, the companies said.
Financial terms were not disclosed. — Anisa Jibrell